These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 28760370)

  • 1. What NMR can do in the biopharmaceutical industry.
    Kiss R; Fizil Á; Szántay C
    J Pharm Biomed Anal; 2018 Jan; 147():367-377. PubMed ID: 28760370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein NMR of biologicals: analytical support for development and marketed products.
    Casagrande F; Dégardin K; Ross A
    J Biomol NMR; 2020 Nov; 74(10-11):657-671. PubMed ID: 32350692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Comparison Between Emerging and Current Biophysical Methods for the Assessment of Higher-Order Structure of Biopharmaceuticals.
    Wen J; Batabyal D; Knutson N; Lord H; Wikström M
    J Pharm Sci; 2020 Jan; 109(1):247-253. PubMed ID: 31669605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biosimilar structural comparability assessment by NMR: from small proteins to monoclonal antibodies.
    Japelj B; Ilc G; Marušič J; Senčar J; Kuzman D; Plavec J
    Sci Rep; 2016 Aug; 6():32201. PubMed ID: 27578487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Considerations of critical quality attributes in the analytical comparability assessment of biosimilar products.
    Kwon O; Joung J; Park Y; Kim CW; Hong SH
    Biologicals; 2017 Jul; 48():101-108. PubMed ID: 28495312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NMR based quality evaluation of mAb therapeutics: A proof of concept higher order structure biosimilarity assessment of trastuzumab biosimilars.
    Joshi S; Khatri LR; Kumar A; Rathore AS
    J Pharm Biomed Anal; 2022 May; 214():114710. PubMed ID: 35290923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aqueous two-phase systems: A viable platform in the manufacturing of biopharmaceuticals.
    Rosa PA; Ferreira IF; Azevedo AM; Aires-Barros MR
    J Chromatogr A; 2010 Apr; 1217(16):2296-305. PubMed ID: 19962707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Precision and robustness of 2D-NMR for structure assessment of filgrastim biosimilars.
    Ghasriani H; Hodgson DJ; Brinson RG; McEwen I; Buhse LF; Kozlowski S; Marino JP; Aubin Y; Keire DA
    Nat Biotechnol; 2016 Feb; 34(2):139-41. PubMed ID: 26849514
    [No Abstract]   [Full Text] [Related]  

  • 9. NMR spectroscopy tools for structure-aided drug design.
    Homans SW
    Angew Chem Int Ed Engl; 2004 Jan; 43(3):290-300. PubMed ID: 14705081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hybrid modeling for quality by design and PAT-benefits and challenges of applications in biopharmaceutical industry.
    von Stosch M; Davy S; Francois K; Galvanauskas V; Hamelink JM; Luebbert A; Mayer M; Oliveira R; O'Kennedy R; Rice P; Glassey J
    Biotechnol J; 2014 Jun; 9(6):719-26. PubMed ID: 24806479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of the higher order structure of Humira®, Remicade®, Avastin®, Rituxan®, Herceptin®, and Enbrel® by 2D-NMR fingerprinting.
    Hodgson DJ; Ghasriani H; Aubin Y
    J Pharm Biomed Anal; 2019 Jan; 163():144-152. PubMed ID: 30296716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-field EPR on membrane proteins - crossing the gap to NMR.
    Möbius K; Lubitz W; Savitsky A
    Prog Nucl Magn Reson Spectrosc; 2013 Nov; 75():1-49. PubMed ID: 24160760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biosimilarity Versus Manufacturing Change: Two Distinct Concepts.
    Declerck P; Farouk-Rezk M; Rudd PM
    Pharm Res; 2016 Feb; 33(2):261-8. PubMed ID: 26381277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in protein NMR spectroscopy and their implications in protein therapeutics research.
    Wang G; Zhang ZT; Jiang B; Zhang X; Li C; Liu M
    Anal Bioanal Chem; 2014 Apr; 406(9-10):2279-88. PubMed ID: 24309626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enabling adoption of 2D-NMR for the higher order structure assessment of monoclonal antibody therapeutics.
    Brinson RG; Marino JP; Delaglio F; Arbogast LW; Evans RM; Kearsley A; Gingras G; Ghasriani H; Aubin Y; Pierens GK; Jia X; Mobli M; Grant HG; Keizer DW; Schweimer K; Ståhle J; Widmalm G; Zartler ER; Lawrence CW; Reardon PN; Cort JR; Xu P; Ni F; Yanaka S; Kato K; Parnham SR; Tsao D; Blomgren A; Rundlöf T; Trieloff N; Schmieder P; Ross A; Skidmore K; Chen K; Keire D; Freedberg DI; Suter-Stahel T; Wider G; Ilc G; Plavec J; Bradley SA; Baldisseri DM; Sforça ML; Zeri ACM; Wei JY; Szabo CM; Amezcua CA; Jordan JB; Wikström M
    MAbs; 2019 Jan; 11(1):94-105. PubMed ID: 30570405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical development and trial design of biosimilar products: a Japanese perspective.
    Nagasaki M; Ando Y
    J Biopharm Stat; 2014; 24(6):1165-72. PubMed ID: 25033370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of Natural Isotopic Abundance ¹H-¹³C- and ¹H-¹⁵N-Correlated Two-Dimensional NMR for Evaluation of the Structure of Protein Therapeutics.
    Arbogast LW; Brinson RG; Marino JP
    Methods Enzymol; 2016; 566():3-34. PubMed ID: 26791974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extractables from integrated single-use systems in biopharmaceutical manufacturing. Part I. Study on components (Pall Kleenpak connector and Kleenpak filter capsule).
    Ding W; Nash R
    PDA J Pharm Sci Technol; 2009; 63(4):322-38. PubMed ID: 20088246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medium term planning of biopharmaceutical manufacture using mathematical programming.
    Lakhdar K; Zhou Y; Savery J; Titchener-Hooker NJ; Papageorgiou LG
    Biotechnol Prog; 2005; 21(5):1478-89. PubMed ID: 16209554
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.